Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference

Morphic Therapeutic (NASDAQ: MORF) has announced its participation in the Jefferies Virtual London Healthcare Conference, with a presentation scheduled for November 18, 2020, at 2:55 PM ET.

Rhea-AI Summary

Morphic Therapeutic (NASDAQ: MORF) has announced its participation in the Jefferies Virtual London Healthcare Conference, with a presentation scheduled for November 18, 2020, at 2:55 PM ET. The event will feature insights into Morphic's innovative oral therapies targeting integrins for serious chronic diseases. Investors can access a live webcast of the presentation on the company’s website, with an archived replay available afterward. Morphic Therapeutic is advancing its pipeline using its proprietary MInT technology platform, in collaboration with AbbVie, Janssen, and Schrödinger.

Argus Session date unavailable

-0.30% session move Open Argus

Details

News Market Reaction – MORF

The recorded move for MORF in the trading session of this news was -0.30%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020.

A live webcast of the company presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts

Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com 
617.686.1718

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Morphic Therapeutic's presentation at the Jefferies Virtual London Healthcare Conference?

Morphic Therapeutic's presentation is scheduled for November 18, 2020, at 2:55 PM ET.

Where can I watch the Morphic Therapeutic conference presentation live?

You can watch the live webcast of the presentation on Morphic's investor website.

What is Morphic Therapeutic's focus in biopharmaceuticals?

Morphic Therapeutic focuses on developing oral integrin therapies for serious chronic diseases.

Who are Morphic Therapeutic's collaborators in their research?

Morphic Therapeutic collaborates with AbbVie, Janssen, and Schrödinger.

What is the MInT technology platform used by Morphic Therapeutic?

The MInT technology platform is Morphic's proprietary method leveraging their understanding of integrin structure and biology.